News

20262025202420232022

New Platform Combines Precision Gene Targeting with Brain-Wide Delivery

Wednesday, July 8, 2026

A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain. The approach addresses two major challenges in neurological medicine—reaching therapeutic targets behind the blood-brain barrier and limiting unwanted effects elsewhere in the body—and could pave the way for new treatments for diseases including multiple sclerosis, Huntington's disease, and rare childhood white matter disorders.

The platform pairs specially engineered adeno-associated viruses (AAVs) with a delivery strategy that harnesses the brain's natural fluid transport pathways. Together, these innovations enabled researchers to deliver therapeutic genes broadly throughout the brain, preferentially targeting human glial cells while minimizing exposure to other cell types and organs.

“Gene delivery to the brain has always faced two major obstacles,” said Steve Goldman, MD, PhD, co-director of the University of Rochester Medicine Center for Translational Neuromedicine and lead author of the study, which appears in Nature Biotechnology. “You need a way to get therapies into the brain selectively and efficiently, and you need vectors that can deliver those therapies to the right cells once they get there. This work addresses both challenges simultaneously.”